N-terminal fragment of cardiac myosin binding protein-C triggers pro-inflammatory responses in vitro

Journal of Molecular and Cellular Cardiology

Volumn 99, Issue , 2016, Pages 47-56

  Lipps, Christoph ^a   Nguyen, Jenine H ^a   Pyttel, Lukas ^b   Lynch, Thomas L ^c   Liebetrau, Christoph ^b   Aleshcheva, Ganna ^b   Voss, Sandra ^b   Dörr, Oliver ^a   Nef, Holger M ^a   Möllmann, Helge ^b   Hamm, Christian W ^a,b   Sadayappan, Sakthivel ^c   Troidl, Christian ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Kerckhoff Heart and Thorax Center   (Germany)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

C0C1f; Cardiac myosin binding protein C; Cell signaling signal transduction; Inflammation; Ischemic biology basic studies; Myocardial infarction

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CARDIAC MYOSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYOSIN BINDING PROTEIN C; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; AUTACOID; CARRIER PROTEIN; CYTOKINE; MYOSIN-BINDING PROTEIN C;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL ACTIVATION; CONTROLLED STUDY; HEART INFARCTION; HEART INJURY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MACROPHAGE ACTIVATION; MACROPHAGE CULTURE; MONOCYTE; MONOCYTE CULTURE; MOUSE; MYOCARDITIS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; STRUCTURE ACTIVITY RELATION; UPREGULATION; ANIMAL; CHEMISTRY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; CARRIER PROTEINS; CYTOKINES; GENE EXPRESSION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; MICE; MONOCYTES; NF-KAPPA B; PROTEIN INTERACTION DOMAINS AND MOTIFS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84987646135     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.09.003     Document Type: Article

References (35)

1. [1] Frangogiannis, N.G., The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J. Cardiovasc. Pharmacol. 63 (2014), 185–195.
2. [2] Dutta, P., Nahrendorf, M., Monocytes in myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 1066–1070.
3. [3] Hulsmans, M., Sam, F., Nahrendorf, M., Monocyte and macrophage contributions to cardiac remodeling. J. Mol. Cell. Cardiol., 2015.
4. [4] Troidl, C., Jung, G., Troidl, K., Hoffmann, J., Mollmann, H., Nef, H., et al. The temporal and spatial distribution of macrophage subpopulations during arteriogenesis. Curr. Vasc. Pharmacol. 11 (2013), 5–12.
5. [5] de Haan, J.J., Smeets, M.B., Pasterkamp, G., Arslan, F., Danger signals in the initiation of the inflammatory response after myocardial infarction. Mediat. Inflamm., 2013, 2013, 206039.
6. [6] Land, W.G., The role of damage-associated molecular patterns (DAMPs) in human diseases: part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. Sultan Qaboos Univ. Med. J. 15 (2015), e157–e170.
7. [7] Jacquet, S., Yin, X., Sicard, P., Clark, J., Kanaganayagam, G.S., Mayr, M., et al. Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol. Cell. Proteomics 8 (2009), 2687–2699.
8. [8] Govindan, S., Sarkey, J., Ji, X., Sundaresan, N.R., Gupta, M.P., de Tombe, P.P., et al. Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro. J. Muscle Res. Cell Motil. 33 (2012), 17–30.
9. [9] Govindan, S., McElligott, A., Muthusamy, S., Nair, N., Barefield, D., Martin, J.L., et al. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J. Mol. Cell. Cardiol. 52 (2012), 154–164.
10. [10] Weith, A., Sadayappan, S., Gulick, J., Previs, M.J., Vanburen, P., Robbins, J., et al. Unique single molecule binding of cardiac myosin binding protein-C to actin and phosphorylation-dependent inhibition of actomyosin motility requires 17 amino acids of the motif domain. J. Mol. Cell. Cardiol. 52 (2012), 219–227.
11. [11] Baker, J.O., Tyther, R., Liebetrau, C., Clark, J., Howarth, R., Patterson, T., et al. Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. Basic Res. Cardiol., 110, 2015, 23.
12. [12] Lynch, T.L., Sadayappan, S., Surviving the infarct: a profile of cardiac myosin binding protein-C pathogenicity, diagnostic utility, and proteomics in the ischemic myocardium. Proteomics Clin. Appl. 8 (2014), 569–577.
13. [13] Witayavanitkul, N., Ait Mou, Y., Kuster, D.W., Khairallah, R.J., Sarkey, J., Govindan, S., et al. Myocardial infarction-induced N-terminal fragment of cardiac myosin-binding protein C (cMyBP-C) impairs myofilament function in human myocardium. J. Biol. Chem. 289 (2014), 8818–8827.
14. [14] Zanoni, I., Ostuni, R., Capuano, G., Collini, M., Caccia, M., Ronchi, A.E., et al. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature 460 (2009), 264–268.
15. [15] Copeland, O., Sadayappan, S., Messer, A.E., Steinen, G.J., van der Velden, J., Marston, S.B., Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. J. Mol. Cell. Cardiol. 49 (2010), 1003–1011.
16. [16] Lawrence, T., The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb. Perspect. Biol., 1, 2009, a001651.
17. [17] Pierce, J.W., Schoenleber, R., Jesmok, G., Best, J., Moore, S.A., Collins, T., et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272 (1997), 21096–21103.
18. [18] Ii, M., Matsunaga, N., Hazeki, K., Nakamura, K., Takashima, K., Seya, T., et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 69 (2006), 1288–1295.
19. [19] Frangogiannis, N.G., Regulation of the inflammatory response in cardiac repair. Circ. Res. 110 (2012), 159–173.
20. [20] Jivraj, N., Phinikaridou, A., Shah, A.M., Botnar, R.M., Molecular imaging of myocardial infarction. Basic Res. Cardiol. 109 (2013), 1–16.
21. [21] Piccinini, A.M., Midwood, K.S., DAMPening inflammation by modulating TLR signalling. Mediat. Inflamm., 2010, 2010.
22. [22] Andrassy, M., Volz, H.C., Igwe, J.C., Funke, B., Eichberger, S.N., Kaya, Z., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117 (2008), 3216–3226.
23. [23] Chiong, M., Wang, Z.V., Pedrozo, Z., Cao, D.J., Troncoso, R., Ibacache, M., et al. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis., 2, 2011, e244.
24. [24] Liebetrau, C., Hoffmann, J., Dorr, O., Gaede, L., Blumenstein, J., Biermann, H., et al. Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction. Circ. Res. 116 (2015), 867–875.
25. [25] Razzaque, M.A., Gupta, M., Osinska, H., Gulick, J., Blaxall, B.C., Robbins, J., An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure. Circ. Res. 113 (2013), 553–561.
26. [26] Harris, S.P., Lyons, R.G., Bezold, K.L., In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ. Res. 108 (2011), 751–764.
27. [27] Marjot, J., Liebetrau, C., RJ, G., Kaier, T., Weber, E., Heseltine, P., et al. The development and application of a high-sensitivity immunoassay for cardiac myosin-binding protein C. Transl. Res., 2015.
28. [28] Richardson, P., McKenna, W., Bristow, M., Maisch, B., Mautner, B., O'Connell, J., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93 (1996), 841–842.
29. [29] Caforio, A.L., Role of autoimmunity in dilated cardiomyopathy. Br. Heart J. 72 (1994), S30–S34.
30. [30] Kasahara, H., Itoh, M., Sugiyama, T., Kido, N., Hayashi, H., Saito, H., et al. Autoimmune myocarditis induced in mice by cardiac C-protein. Cloning of complementary DNA encoding murine cardiac C-protein and partial characterization of the antigenic peptides. J. Clin. Invest. 94 (1994), 1026–1036.
31. [31] Lipps, C., May, T., Hauser, H., Wirth, D., Eternity and functionality - rational access to physiologically relevant cell lines. Biol. Chem. 394 (2013), 1637–1648.
32. [32] Lavine, K.J., Epelman, S., Uchida, K., Weber, K.J., Nichols, C.G., Schilling, J.D., et al. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 16029–16034.
33. [33] Cohen Heather, B., Mosser, D.M., Cardiac macrophages: how to mend a broken heart. Immunity 40 (2014), 3–5.
34. [34] Platzer, C., Meisel, C., Vogt, K., Platzer, M., Volk, H.-D., Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int. Immunol. 7 (1995), 517–523.
35. [35] Ibrahim, Z.A., Armour, C.L., Phipps, S., Sukkar, M.B., RAGE and TLRs: relatives, friends or neighbours?. Mol. Immunol. 56 (2013), 739–744.